
Che-Kai Tsao, MD
Internal Medicine, Cancer (Oncology)
About Me
Kai Tsao MD MS is the Medical Director of the Ruttenberg Treatment Center at the Mount Sinai Hospital, and the Medical Director of the Medical Oncology Prostate Cancer Program at the Tisch Cancer Institute. He is an Associate Professor of Hematology, Oncology, and Medicine at the Icahn School of Medicine at Mount Sinai. He was the Chief Fellow during his Hematology and Oncology fellowship training, and is the recipient of the annual Mount Sinai Hospital Fellow Physician of the year award in 2012. As a physician-clinical investigator specialized in genitourinary cancers, he has authored over 70 peer reviewed paper to date, and is the recipient of several research awards from the American Society of Clinical Oncology (ASCO). His research focus is on the development of biomarkers and novel therapies for Prostate and Kidney cancers. He is the principal investigator of numerous ongoing phase I-III clinical trials. He is currently the reviewer and editor of several urology and oncology peer reviewed journals, and is regularly invited to lecture globally. He is the recipient of Tisch Cancer Institute’s Solid Tumor faculty teacher of the year in 2023.
With focus in improving healthcare delivery, he completed Lean Six Sigma training at Johns Hopkins University in 2017, and completed the Masters of Healthcare Delivery at the Icahn School of Medicine in 2019. He is a disciple of patient-centered care, using a combination of data-driven analytics and LEAN principles in improving cancer care. He has led several international oncology collaborations on behalf of Mount Sinai International, in countries including Vietnam, China, Guyana, and India. In this role since 2017, he has led teams of multi-disciplinary experts in collaboration with international partners to develop healthcare delivery strategy, improve cancer center and hospital infrastructure, implement quality driven process improvement, and prepare for Joint Commission International accreditation.
Language
Position
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
Research Topics
Cancer, Cancer Genetics, Clinical Genomics, Genomics, Immunology, Kidney, Prostate, Translational Research
About Me
Kai Tsao MD MS is the Medical Director of the Ruttenberg Treatment Center at the Mount Sinai Hospital, and the Medical Director of the Medical Oncology Prostate Cancer Program at the Tisch Cancer Institute. He is an Associate Professor of Hematology, Oncology, and Medicine at the Icahn School of Medicine at Mount Sinai. He was the Chief Fellow during his Hematology and Oncology fellowship training, and is the recipient of the annual Mount Sinai Hospital Fellow Physician of the year award in 2012. As a physician-clinical investigator specialized in genitourinary cancers, he has authored over 70 peer reviewed paper to date, and is the recipient of several research awards from the American Society of Clinical Oncology (ASCO). His research focus is on the development of biomarkers and novel therapies for Prostate and Kidney cancers. He is the principal investigator of numerous ongoing phase I-III clinical trials. He is currently the reviewer and editor of several urology and oncology peer reviewed journals, and is regularly invited to lecture globally. He is the recipient of Tisch Cancer Institute’s Solid Tumor faculty teacher of the year in 2023.
With focus in improving healthcare delivery, he completed Lean Six Sigma training at Johns Hopkins University in 2017, and completed the Masters of Healthcare Delivery at the Icahn School of Medicine in 2019. He is a disciple of patient-centered care, using a combination of data-driven analytics and LEAN principles in improving cancer care. He has led several international oncology collaborations on behalf of Mount Sinai International, in countries including Vietnam, China, Guyana, and India. In this role since 2017, he has led teams of multi-disciplinary experts in collaboration with international partners to develop healthcare delivery strategy, improve cancer center and hospital infrastructure, implement quality driven process improvement, and prepare for Joint Commission International accreditation.
Language
Position
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
Research Topics
Cancer, Cancer Genetics, Clinical Genomics, Genomics, Immunology, Kidney, Prostate, Translational Research
Clinical Focus
- Bladder Cancer
- Cancer Treatment
- Kidney Cancer
- Prostate Cancer
- Testicular Cancer
Education
MD, SUNY Downstate Health Sciences University - College of Medicine
MS, Icahn School of Medicine at Mount Sinai
Residency, Internal Medicine
Long Island Jewish Medical Center
Fellowship, Hematology & Oncology
Mount Sinai Hospital
Certifications
American Board of Internal Medicine
Awards
2023
Solid Tumor Faculty Teaching Award
Tisch Cancer Institute, Mount Sinai Hospital
2012
Merit Award
American Society of Clinical Oncology
2012
GU Cancers Merit Award
American Society of Clinical Oncology
2012
Physician of the Year, Fellow Award
Mount Sinai Hospital
2011
Workshop on Methods in Clinical Cancer Research
ASCO/AACR
2011
Oncology Trainee Travel Award
American Society of Clinical Oncology
Research
Insurance Information
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Characterization of Exceptional Responses in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Cabozantinib and Immune Checkpoint Inhibitors. Teja Ganta, Jonathan F. Anker, Eric Miller, Himanshu Joshi, Che Kai Tsao, William K. Oh. Clinical Genitourinary Cancer
- A Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions. Parissa Alerasool, Susu Zhou, Eric Miller, Jonathan Anker, Brandon Tsao, Natasha Kyprianou, Che Kai Tsao. Cancers
- A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials. Paul Leger, Stanley Frencher, Jones T. Nauseef, Brian Jones, Mehmet A. Bilen, Alan Brown, Aminha Ullah, Shane McDevitt, Che Kai Tsao. Future Oncology
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Tsao during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Lantheus Medical
- Bayer AG
- Pfizer Inc., U.S. Pharmaceuticals Group
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Tsao during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Lantheus Medical
- Bayer AG
- Pfizer Inc., U.S. Pharmaceuticals Group
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.